Success Stories: EB-1A Approved for Research Associate in California in the Field of Molecular Biology
Client’s Testimonial:
Woo, Thank you so much. I am so happy and I really appreciate all your help. It is my great pleasure to let other people know your beautiful work. [...] Thanks again for the good news!
On August 10th, 2015, We Received another EB1-A (Alien of Extraordinary Ability) Approval for a Research Associate in the Field of Molecular Biology (Approval Notice)
Position at the Time of Case Filing: Research Associate
Country of Origin: China
Service Center: Nebraska Service Center (NSC)
State of Residence at the Time of Filing: California
Approval Notice Date: August 10th, 2015
Processing Time: 4 Months, 10 Days
In this case, the client that we had the opportunity to work with was a research associate from China in the field of molecular biology. Specifically, our client’s specialized research has focused on the study of cancer, neurodegenerative diseases, cell signaling pathways, novel biomedical therapies, and oncolytic adenovirus optimization for cancer treatments, among other critical realms of research. Her work had resulted in 10 peer-reviewed scientific articles, numerous presentations at national and international conferences, and 1 book chapter; at the time that her case was filed, her publications had been cited at least 141 times by independent and leading researchers from prestigious institutions and organizations around the world, indicating the major significance of her work. She had also reviewed 41 manuscripts for 13 distinctive, internationally-circulated journals. Her superior level of expertise was confirmed in the following quote from an independent recommender, “[Client] is a prevailing leader in the study of Charcot-Marie-Tooth (CMT) disease and other neurodegenerative ailments, her experiments uncovering results and functions never before grasped in biochemical science...By helping us to understand the apparatuses accountable in disease prevention or, conversely, influential in provoking disease, [client] answers the fundamental questions of pathology that herald a new age of effective disease control based on conscientious and informed drug design.” It was our goal to prove that our client qualified for classification as an Alien of Extraordinary Ability given that she sought to remain in the United States to continue work in the area of molecular biology, and that her continued research would substantially and prospectively benefit the United States. With the proof and documentation that we provided, her case was approved in 4 months and 10 days.